This trial has completed recruitment on this platform, and is no longer accepting new referrals.
The purpose of the BabyCOVE Study is to assess the safety and effectiveness of an investigational vaccine against SARS-CoV-2 in infants 12–26 weeks old.
The BabyCOVE Study will be conducted in 2 parts:
All participants will receive 2 doses, 8 weeks apart.
Sites are located in the cities/states identified with the red pin:
Participation in this clinical trial lasts up to 15 months and includes up to 8 in-person visits and up to 2 virtual visits with the clinical trial staff.
Participants will receive 2 vaccinations, approximately 8 weeks apart (Day 1 and Day 57).
At in-person visits, the clinical trial staff will perform a physical exam, sometimes including a nasal swab and blood draw.
Participants’ parents will be asked to use an eDiary app on their personal smartphone or a provided device to answer prompts and report any symptoms their child experiences.
Insurance is not needed to join this clinical trial, and compensation for trial-related time may be available.